A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

NCT04102124 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Stopped The sponsor's R\&D strategy is adjusted.

Conditions

Prostate Cancer
Castration-resistant Prostate Cancer

Interventions

DRUG: SHR3680
DRUG: SHR3162
DRUG: SHR3680(Placebo)
DRUG: SHR3162(Placebo)

Sponsor

Jiangsu HengRui Medicine Co., Ltd.